Fundación EPIC

fundacionepic.org

Total trials

48

Active

30

Phase 3

0

Total enrollment

20,906

Read this sponsor's pipeline like an analyst.

Generate a written report: strategic focus, priority programs, pipeline shape, recent terminations and momentum, and the trials worth watching in the next 12 months.

~15-30 sec · cached for 24h

Pipeline matrix

Showing 5 of 5 active programs · click any cell for trials

InterventionEarly Phase 1Phase 1Phase 2Phase 3Phase 4N/ATotal
Clopidogrel1
Previous treatment1
Polypill of acetylsalicylic acid, ramipril and atorvastatin1
Drugs taken separately: acetylsalicylic acid, ramipril and atorvastatin1
Single antiplatelet therapy1

Next readouts

  • 2026-03-30
  • 2026-10-01
  • 2026-12-03

Top conditions

  • Coronary Artery Disease25
  • Ischemic Heart Disease18
  • Coronary Artery Disease (CAD)8
  • Cardiovascular Diseases6
  • Coronary Disease5
  • Atrial Fibrillation3
  • Aortic Valve Stenosis3
  • Heart Diseases3

Frequently asked questions about Fundación EPIC

How many clinical trials does Fundación EPIC have on ClinicalTrials.gov?
Fundación EPIC is listed as the lead sponsor on 48 clinical trials in ClinicalTrials.gov, 30 of which are currently active (recruiting, enrolling, or ongoing).
How many of Fundación EPIC's trials are in Phase 3?
0 of Fundación EPIC's trials are in Phase 3, spread across 5 active drug programs.
What therapeutic areas does Fundación EPIC focus on?
Fundación EPIC's most-studied conditions on ClinicalTrials.gov are Coronary Artery Disease, Ischemic Heart Disease, Coronary Artery Disease (CAD), Cardiovascular Diseases, Coronary Disease.
When are Fundación EPIC's next clinical trial readouts?
Fundación EPIC has 3 upcoming primary-completion readouts tracked here; the soonest is “Cross-over Study of Coronary Risk Factors With a Polypill”, expected around 2026-03-30.